Paper32943751
Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
Yang Y and 27 others. Leukemia, 2021. Cited by 30 papers, by iCite.
Cite this record
ConductScience Library. Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. Papers, record 32943751. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/32943751
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study.
- PubMed
Topics11
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Lymphoma, Extranodal NK-T-Cell | Major topic |
| Adult | |
| Combined Modality Therapy | |
| Female | |
| Follow-Up Studies | |
| Humans | |
| Male | |
| Middle Aged | |
| Prognosis | |
| Retrospective Studies | |
| Survival Rate |
Source PubMed
Comments and corrections1
PubMed's comments and corrections, NLM's own indexing: retractions first, then expressions of concern, errata and updates, and comments last.
| Kind | PMID | Title | In Papers |
|---|---|---|---|
| Erratum in | 34341480 | Correction to: Progression-free survival at 24 months and subsequent survival of patients with extranodal NK/T-cell lymphoma: a China Lymphoma Collaborative Group (CLCG) study. | https://conductscience.org/library/papers/34341480 |
Source PubMed
Cited by23
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 30 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42591107 | Survival analysis and prognostic factors of mature T-cell and natural killer/T-cell neoplasms in Colombian patients from 2008-2025. | Front Oncol | 2026 | https://conductscience.org/library/papers/42591107 | PubMed |
| 42414740 | Development and validation of a radiomics nomogram for predicting outcomes following combined radiotherapy and modern chemotherapy in early-stage extranodal nasal-type NK/T-cell lymphoma: a multicenter study. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42414740 | PubMed |
| 42400641 | The increased co-expression of SLC7A11 and PD-L1 was associated with poor prognosis in extranodal natural killer T-cell lymphoma patients. | Cancer Immunol Immunother | 2026 | https://conductscience.org/library/papers/42400641 | PubMed |
| 42154282 | Lactate dehydrogenase/albumin ratio predicts progression of disease within 24 months (POD24) in advanced-stage extranodal natural killer/T cell lymphoma. | Ann Hematol | 2026 | https://conductscience.org/library/papers/42154282 | PubMed |
| 42022040 | Development and validation of a multiparameter prognostic model for extranodal natural killer/T-cell lymphoma: Integration of clinical, pathological, and molecular biomarkers. | Cytojournal | 2026 | https://conductscience.org/library/papers/42022040 | PubMed |
| 41613778 | Failure patterns and clinical indications in early-stage follicular lymphoma: a study from the National Cancer Center in China. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/41613778 | PubMed |
| 41552766 | Synchronous primary pulmonary extranodal NK/T-cell lymphoma and relapsed Hodgkin lymphoma occurring after chemotherapy for primary Hodgkin lymphoma: A case report and literature review. | Rare Tumors | 2026 | https://conductscience.org/library/papers/41552766 | PubMed |
| 40115906 | Subsequent Survival and Loss of Lifetime for Patients With Progression-Free 24 Months After Treatment in Nasopharyngeal Carcinoma: A Comprehensive Nationwide Population-Based Analysis. | MedComm (2020) | 2025 | https://conductscience.org/library/papers/40115906 | PubMed |
| 39144825 | Challenges in overcoming advanced-stage or relapsed refractory extranodal NK/T-cell lymphoma: meta-analysis of individual patient data. | Front Oncol | 2024 | https://conductscience.org/library/papers/39144825 | PubMed |
| 38783159 | Increased coexpression of PD-L1 and IDO1 is associated with poor overall survival in patients with NK/T-cell lymphoma. | Leukemia | 2024 | https://conductscience.org/library/papers/38783159 | PubMed |
| 38604793 | [Efficacy and safety analysis of P-GemDOx regimen and stratified prognosis in patients with early extranodal NK/T cell lymphoma]. | Zhonghua Xue Ye Xue Za Zhi | 2024 | https://conductscience.org/library/papers/38604793 | PubMed |
| 38040859 | Clinical significance and predictive risk factors for event-free survival at 24 months in patients with PTCL, NOS. | Ann Hematol | 2024 | https://conductscience.org/library/papers/38040859 | PubMed |
| 37558851 | Prognostic value of POD18 combined with improved IELSG in primary central nervous system lymphoma. | Clin Transl Oncol | 2024 | https://conductscience.org/library/papers/37558851 | PubMed |
| 37351807 | Comparative analysis of upper aerodigestive tract and non-upper aerodigestive tract in NK/T-cell lymphoma. | Clin Transl Oncol | 2024 | https://conductscience.org/library/papers/37351807 | PubMed |
| 37345104 | Difference in Efficacy and Safety of Anti-CD19 Chimeric Antigen Receptor T-Cell Therapy Containing 4-1BB and CD28 Co-Stimulatory Domains for B-Cell Acute Lymphoblastic Leukemia. | Cancers (Basel) | 2023 | https://conductscience.org/library/papers/37345104 | PubMed |
| 37306711 | Outcome and risk prediction of early progression in patients with extranodal natural killer/T cell lymphoma from the CLCG study. | Ann Hematol | 2023 | https://conductscience.org/library/papers/37306711 | PubMed |
| 37181228 | Etoposide, dexamethasone, and pegaspargase with sandwiched radiotherapy in early-stage natural killer/T-cell lymphoma: A randomized phase III study. | Innovation (Camb) | 2023 | https://conductscience.org/library/papers/37181228 | PubMed |
| 36951150 | Evidence of cure for extranodal nasal-type natural killer/T-cell lymphoma with current treatment: an analysis of the CLCG database. | Haematologica | 2023 | https://conductscience.org/library/papers/36951150 | PubMed |
| 36825002 | Treatment of extranodal NK/T-cell lymphoma: From past to future. | Front Immunol | 2023 | https://conductscience.org/library/papers/36825002 | PubMed |
| 36819187 | Characteristics and prognosis of distant metastasis after primary treatment for early-stage extranodal nasal-type natural killer/T-cell lymphoma from the China Lymphoma Collaborative Group database. | EJHaem | 2023 | https://conductscience.org/library/papers/36819187 | PubMed |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- References
- Genes
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/32943751
GET https://conductscience.org/api/papers/v1/32943751/authors?page=2